Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:36:03.877Z.
Calculation as of: 2026-10-06T17:36:03.877Z.
Quote observation: 2026-10-06T17:35:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4980e4284b6230c79d3dcd5f09fe919c7c05eb80d65ab6e095ba480293e97312
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Canton Strategic Holdings Inc (CNTN) | $183.94M | N/A | N/A | N/A | N/A |
| AN2 Therapeutics, Inc. (ANTX)vs › | $183.32M | N/A | N/A | N/A | N/A |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $181.71M | 1.08 | 2.35 | 8.36 | 8.36 |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $188.64M | N/A | N/A | N/A | N/A |
| Yarrow Bioscience Inc (YARW)vs › | $177.62M | N/A | N/A | N/A | N/A |
| RxSight, Inc. (RXST)vs › | $191.67M | N/A | N/A | N/A | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $175.66M | N/A | N/A | N/A | N/A |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.94M | N/A | N/A | N/A | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $172.84M | N/A | N/A | N/A | N/A |
| Precision BioSciences, Inc. (DTIL)vs › | $172.65M | N/A | 11.57 | 11.57 | 11.57 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$2.38
Forward EPS (Est.)
$-0.75
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
